Affinage

FBXO2

F-box only protein 2 · UniProt Q9UK22

Length
296 aa
Mass
33.3 kDa
Annotated
2026-04-28
48 papers in source corpus 30 papers cited in narrative 30 extracted findings

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

FBXO2 is a substrate-recognition subunit of the SCF (SKP1-CUL1-F-box) E3 ubiquitin ligase complex that targets glycoproteins and non-glycoprotein substrates for ubiquitin-dependent degradation, functioning in ER-associated quality control, innate immunity, organelle homeostasis, and signaling regulation across neuronal and non-neuronal tissues. Its sugar-binding domain (SBD) recognizes high-mannose N-linked glycans (Man3GlcNAc2 core) on substrates including APP, GluN1, insulin receptor, CFTR, EBV glycoprotein B, and bacterial surface carbohydrates, directing them for K48-linked polyubiquitination and proteasomal degradation, while also mediating lysophagy and xenophagy by detecting exposed glycan moieties on damaged lysosomes and intracellular bacteria (PMID:15857118, PMID:24469452, PMID:27932386, PMID:30052682, PMID:32931479, PMID:34515398). Beyond glycan-dependent recognition, FBXO2 ubiquitinates non-glycosylated substrates (KPTN, WEE1, p53, USP49, YTHDF2, LCN2) through its F-box-associated (FBA) domain, thereby modulating mTORC1 signaling, cell cycle progression, ferroptosis, and mitophagy (PMID:41401028, PMID:40676478, PMID:39343799, PMID:40791152). In vivo, the majority of FBXO2 exists as Fbs1-Skp1 heterodimers rather than canonical SCF complexes, and this heterodimer independently suppresses glycoprotein aggregation as a chaperone; Fbxo2 knockout mice develop age-related cochlear degeneration and elevated NMDA receptor subunit levels, demonstrating its physiological importance in neuronal proteostasis (PMID:17215248, PMID:17494702, PMID:25878288).

Mechanistic history

Synthesis pass · year-by-year structured walk · 10 steps
  1. 1998 Medium

    Establishing that FBXO2 is an F-box protein in the ubiquitin-proteasome pathway resolved its molecular identity: interaction with Skp1 and F-box-dependent growth inhibition placed it within the SCF E3 ligase family.

    Evidence Co-immunoprecipitation with Skp1, F-box deletion mutagenesis, and transfection-based proliferation assay in neuroblastoma and CHO cells

    PMID:9857061

    Open questions at the time
    • No endogenous substrate identified
    • Mechanism of growth inhibition not defined
    • SCF complex formation with CUL1/RBX1 not demonstrated
  2. 2003 High

    Identification of HSV-1 UL9 as a phosphorylation-dependent substrate established that FBXO2 can recognize non-glycoprotein targets and linked it to viral latency regulation through nuclear shuttling and cytosolic degradation.

    Evidence Co-expression in 293T, polyubiquitination assay, proteasome inhibitor rescue, yeast two-hybrid; live-cell imaging of nuclear shuttling in neurons

    PMID:12904574 PMID:15010529

    Open questions at the time
    • Physiological relevance in HSV latency in vivo not proven
    • Phosphorylation sites on UL9 required for recognition not mapped
  3. 2005 High

    Defining the glycan specificity of FBXO2's sugar-binding domain for the Man3GlcNAc2 core pentasaccharide answered a central question about how it selects substrates: recognition is based on the conserved high-mannose glycan core rather than protein-protein contacts.

    Evidence In vitro binding assays with synthetic sugar chains and thermodynamic analysis; crystal structures of Skp1-Fbs1 and SBD-glycoprotein complexes

    PMID:15857118 PMID:17389369

    Open questions at the time
    • How FBXO2 distinguishes misfolded from native glycoproteins bearing the same glycan not resolved
    • Structural basis for acceptor lysine selection not fully elucidated
  4. 2007 High

    Discovery that FBXO2 predominantly exists as Fbs1-Skp1 heterodimers (not canonical SCF complexes) and independently functions as a glycoprotein aggregation chaperone revealed a dual-function mechanism distinct from conventional F-box proteins.

    Evidence Gel filtration, immunoprecipitation, in vitro aggregation assay, domain deletion analysis; Fbxo2 KO mouse with cochlear degeneration phenotype

    PMID:17215248 PMID:17494702

    Open questions at the time
    • Regulation of switch between chaperone and E3 ligase modes unknown
    • Cochlear substrate(s) mediating degeneration not identified
  5. 2014 High

    Demonstration that FBXO2 targets APP and NMDA receptor subunit GluN1 for degradation in hippocampal neurons established its role as a neuronal glycoprotein quality-control E3 ligase with consequences for synaptic receptor abundance.

    Evidence In vitro ubiquitination, Fbxo2 KO mouse brain analysis, surface biotinylation, electrophysiology

    PMID:24469452 PMID:25878288

    Open questions at the time
    • Whether FBXO2 acts on newly synthesized versus surface-recycled receptor pools not distinguished
    • Impact on Alzheimer's disease pathology in vivo not tested
  6. 2016 High

    Identification of insulin receptor and ΔF508-CFTR as FBXO2 substrates extended its role from neuronal proteostasis to systemic metabolic regulation and ER-associated degradation of disease-causing misfolded proteins.

    Evidence LC-MS/MS substrate screening, in vitro ubiquitination, adenoviral overexpression/ablation in diabetic mouse models; siRNA knockdown and Cl⁻ transport rescue in primary human airway epithelia

    PMID:27756846 PMID:27932386

    Open questions at the time
    • Glycan-dependence of CFTR recognition not directly shown
    • Whether therapeutic modulation of FBXO2 can rescue CF phenotypes in vivo not tested
  7. 2018 High

    Showing that FBXO2 restricts EBV entry by degrading glycoprotein B via glycan recognition expanded its function to antiviral host defense at the ER level.

    Evidence Co-IP, ubiquitination assay, proteasome inhibitor rescue, viral infectivity assay with FBXO2 knockdown

    PMID:30052682

    Open questions at the time
    • Whether FBXO2 targets glycoproteins of other enveloped viruses not explored
    • In vivo antiviral role not demonstrated
  8. 2020 High

    Establishing FBXO2 as a mediator of lysophagy — recognizing glycan moieties exposed on damaged lysosomal membranes — revealed a fundamentally new class of substrates (organelle membranes) and linked FBXO2 loss to neurodegeneration in Niemann-Pick type C mice.

    Evidence Primary cortical culture KO, lysosomal damage assay, NPC mouse model with Fbxo2 deficiency, survival analysis

    PMID:32931479

    Open questions at the time
    • Specific lysosomal glycoprotein substrates recognized not identified
    • Whether FBXO2 acts upstream or in parallel to galectin-based lysophagy signals not resolved
  9. 2021 High

    Demonstrating that FBXO2 directly ubiquitinates intracellular Group A Streptococcus by recognizing surface GlcNAc residues established it as a pattern-recognition receptor for xenophagy, broadening its role from organelle quality control to cell-autonomous immunity.

    Evidence FBXO2 KO cells, GAS infection assay, ubiquitin accumulation quantification, genetic rescue with SCF components

    PMID:34515398

    Open questions at the time
    • Range of bacterial species recognized unknown
    • Redundancy with other glycan-sensing ubiquitin ligases not assessed
  10. 2025 Medium

    A burst of substrate identifications revealed that FBXO2 ubiquitinates multiple non-glycosylated substrates (KPTN, WEE1, p53, USP49, YTHDF2, LCN2, NR2F2) via its FBA domain, establishing a glycan-independent substrate recognition mode with broad implications for mTORC1 signaling, cell cycle, ferroptosis, and epitranscriptomic regulation.

    Evidence Co-IP/mass spectrometry, site-specific ubiquitination mutagenesis, domain mapping, in vivo xenograft and AAV9-based rescue across multiple cancer types and neuronal systems

    PMID:39343799 PMID:40676478 PMID:40791152 PMID:41035649 PMID:41401028 PMID:41436429 PMID:41461633

    Open questions at the time
    • FBA-domain substrate selectivity determinants not structurally characterized
    • Most non-glycoprotein substrates identified by single labs and await independent replication
    • How glycan-dependent and glycan-independent recognition modes are coordinated or regulated remains unclear

Open questions

Synthesis pass · forward-looking unresolved questions
  • The structural basis of FBA-domain-mediated recognition of non-glycoprotein substrates, the regulatory switch between chaperone and E3 ligase activities, and the relative physiological importance of glycan-dependent versus glycan-independent ubiquitination in vivo remain unresolved.
  • No crystal structure of FBA domain bound to a non-glycoprotein substrate
  • In vivo contribution of individual substrate degradation events to neuronal or metabolic phenotypes not dissected
  • Post-translational regulation of FBXO2 itself (beyond SOX6 transcription) largely unknown

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0140096 catalytic activity, acting on a protein 16 GO:0016874 ligase activity 5 GO:0044183 protein folding chaperone 1
Localization
GO:0005829 cytosol 3 GO:0005764 lysosome 2 GO:0005783 endoplasmic reticulum 2 GO:0005634 nucleus 1
Pathway
R-HSA-392499 Metabolism of proteins 8 R-HSA-1643685 Disease 5 R-HSA-162582 Signal Transduction 4 R-HSA-9612973 Autophagy 3 R-HSA-168256 Immune System 1
Partners
APPGLUN1INSRKPTNLCN2SKP1WEE1YTHDF2
Complex memberships
Fbs1-Skp1 heterodimerSCF(FBXO2)

Evidence

Reading pass · 30 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
1998 NFB42 (FBXO2) contains an F-box motif, interacts with Skp1p (OCP2/SKP1), and full-length NFB42 (but not an F-box deletion mutant) inhibits cell proliferation when transfected into neuroblastoma and CHO cells, placing it in the ubiquitin-proteasome pathway. Transfection-based growth assay, co-immunoprecipitation with Skp1p, F-box deletion mutagenesis The Journal of biological chemistry Medium 9857061
2003 FBXO2 (NFB42) binds the phosphorylated HSV-1 replication initiator protein UL9, leading to its polyubiquitination and degradation by the 26S proteasome; interaction is phosphorylation-dependent. Co-expression in 293T cells, proteasome inhibitor (MG132) rescue, in vivo polyubiquitination assay, yeast two-hybrid Proceedings of the National Academy of Sciences of the United States of America High 12904574
2004 HSV-1 infection induces nuclear shuttling of NFB42 (FBXO2), allowing it to bind nuclear phosphorylated UL9 protein and mediate its export to the cytosol for ubiquitination and proteasomal degradation, thereby promoting viral latency in neurons. Live-cell imaging of nuclear shuttling in 293T cells and primary hippocampal neurons, co-immunoprecipitation, proteasome inhibitor rescue Proceedings of the National Academy of Sciences of the United States of America High 15010529
2004 OCP1 (FBXO2) forms a heterodimeric complex with OCP2 (Skp1) and directly binds connexin 26 (Cx26), as demonstrated by pull-down assays and co-immunoprecipitation from organ of Corti extracts, suggesting Cx26 is a substrate of SCF(OCP1). Electrophoretic mobility-shift assay, pull-down with immobilized OCP1, in vitro transcription-translation binding, co-immunoprecipitation from organ of Corti Hearing research Medium 15109709
2005 Fbs1 (FBXO2) preferentially recognizes the Man3GlcNAc2 core pentasaccharide of N-linked high-mannose glycans; thermodynamic analysis showed the chitobiose and α1→6-linked Man residue are required for binding. In vitro binding assays with chemically synthesized sugar chains, thermodynamic (ITC-type) analysis Journal of medicinal chemistry High 15857118
2007 Crystal structures of the Skp1-Fbs1 complex and Fbs1 sugar-binding domain (SBD) bound to glycoprotein revealed that Fbs1 primarily recognizes Man3GlcNAc2 via the SBD, and a linker segment between the F-box and SBD domains undergoes relative motion potentially enabling recognition of different acceptor lysines for ubiquitination. X-ray crystallography of Skp1-Fbs1 complex and SBD-glycoprotein complex Proceedings of the National Academy of Sciences of the United States of America High 17389369
2007 In vivo, the majority of Fbs1 (FBXO2) exists as Fbs1-Skp1 heterodimers or monomers rather than canonical SCF complexes; restricted SCF complex formation is due to the short linker between the F-box and sugar-binding domains. Additionally, Fbs1 independently suppresses glycoprotein aggregation via its N-terminal sequence, functioning as a chaperone independent of ubiquitin ligase activity. Gel filtration, immunoprecipitation, in vitro aggregation assay, domain deletion analysis The Journal of biological chemistry High 17215248
2007 Fbx2 (FBXO2) knockout mice develop age-related cochlear degeneration beginning at 2 months; cochlear Fbx2 binds Skp1 but forms a novel heterodimeric complex rather than canonical SCF complex in this tissue, as other SCF components show little complex formation with Fbx2/Skp1. Targeted gene knockout mouse model, co-immunoprecipitation, histological analysis, Western blot The Journal of neuroscience : the official journal of the Society for Neuroscience High 17494702
2011 Fbs1 (FBXO2) directly binds Nogo receptor 2 (NgR2) through its substrate recognition domain, leading to NgR2 polyubiquitination and proteasomal degradation. Pull-down assay, co-immunoprecipitation, in vitro binding assay, ubiquitination assay Biochemical and biophysical research communications Medium 22206664
2014 Fbxo2 binds APP (amyloid precursor protein), a high-mannose glycoprotein, and promotes its ubiquitin-mediated degradation; loss of Fbxo2 in knockout mice increases APP levels and its cleavage products in hippocampal neurons, and reduces APP at the cell surface. In vitro ubiquitination assay, Fbxo2 KO mouse brain analysis, cultured hippocampal neurons, hippocampal slices, Western blot The Journal of biological chemistry High 24469452
2015 Loss of Fbxo2 in knockout mice increases GluN1 and GluN2A (but not GluN2B) NMDA receptor subunit levels, promotes greater surface localization of GluN1 and GluN2A, and increases axo-dendritic shaft synapses without altering dendritic spine density or neurophysiology. Fbxo2 KO mouse model, Western blot, surface biotinylation, immunohistochemistry, electrophysiology The Journal of neuroscience : the official journal of the Society for Neuroscience High 25878288
2015 FBG1/FBXO2 degrades misfolded A1AT-Z via both the ubiquitin-proteasome system and Beclin1-dependent autophagy; FBG1 acts as a safety ubiquitin ligase to re-ubiquitinate ER proteins that have undergone de-ubiquitination. Chemical and genetic inhibition of proteasome/autophagy, FBG1 knockdown/overexpression in hepatic cell lines and mice, half-life assay PloS one Medium 26295339
2015 Crystal structure of the Skp1-FBG3 complex at 2.6 Å resolution compared with Fbs1 revealed that four loop regions in FBG3 (β2-β3, β5-β6, β7-β8, β9-β10) prevent formation of the carbohydrate-binding pocket, explaining why FBG3 lacks sugar-binding despite high sequence identity with Fbs1. X-ray crystallography, structure-based mutagenesis PloS one High 26460611
2016 FBXO2 targets the insulin receptor (IR) for ubiquitin-dependent proteasomal degradation as a substrate of SCF(FBXO2); adenoviral overexpression of FBXO2 in mice caused hyperglycemia and insulin resistance, while ablation alleviated diabetic phenotypes in obese mice. Protein purification and LC-MS/MS substrate screening, in vitro ubiquitination, adenoviral overexpression/ablation in mouse models, glucose/insulin tolerance tests Diabetes High 27932386
2016 FBXO2 knockdown partially restores ΔF508-CFTR-mediated Cl⁻ transport in primary human CF airway epithelia, indicating FBXO2 participates in ubiquitin-mediated proteasomal degradation of ΔF508-CFTR as part of distinct multiprotein complexes from SYVN1. siRNA knockdown, CFTR functional Cl⁻ transport assay, CFTR maturation assay in polarized airway epithelia The Journal of biological chemistry Medium 27756846
2018 FBXO2 binds high-mannose N-glycans on EBV glycoprotein B (gB) via its sugar-binding domain and targets gB for ubiquitin-proteasome degradation; FBXO2 depletion stabilizes gB and promotes its transport from ER to plasma membrane, enhancing viral membrane fusion and entry. Co-immunoprecipitation, ubiquitination assay, proteasome inhibitor rescue, gB localization by confocal microscopy, viral infectivity assay, FBXO2 knockdown PLoS pathogens High 30052682
2020 Fbxo2 functions as a component of the SCF ubiquitin ligase complex to mediate CNS lysophagy (clearance of damaged lysosomes); loss of Fbxo2 in mouse primary cortical cultures delayed clearance of damaged lysosomes and decreased viability after lysosomal damage, and Fbxo2 deficiency in an NPC mouse model exacerbated neurodegeneration and reduced survival. Primary cortical culture KO, lysosomal damage assay, live-cell imaging, NPC mouse model with Fbxo2 deficiency, motor function testing, survival analysis JCI insight High 32931479
2020 FBXO2 targets glycosylated FBN1 (fibrillin-1) for ubiquitin-dependent proteasomal degradation; FBXO2-mediated FBN1 degradation promotes endometrial cancer cell proliferation via cell cycle (CDK4, CyclinD1, CyclinD2, CyclinA1) and autophagy (ATG4A, ATG4D) pathways. Ubiquitination-proteome approach for substrate identification, co-immunoprecipitation, ubiquitination assay, RNA-seq pathway analysis, in vitro and in vivo proliferation assays Frontiers in cell and developmental biology Medium 32984335
2020 FBXO2 knockout in osteosarcoma cells stabilizes IL-6 receptor (IL-6R, a glycoprotein substrate), inhibiting STAT3 phosphorylation and downstream target gene expression; the glycoprotein recognition activity of FBXO2 is required for this function. CRISPR-Cas9 KO, immunoprecipitation, STAT3 luciferase reporter assay, in vivo xenograft Cancer cell international Medium 32549792
2021 FBXO2/SCF ubiquitin ligase complex recognizes GlcNAc residues on Group A Streptococcus (GAS) surface carbohydrates via its sugar-binding motif, promoting ubiquitination of intracellular GAS and xenophagic bacterial degradation; FBXO2 knockout reduced ubiquitin accumulation on GAS and impaired xenophagy. FBXO2 KO cells, GAS infection assay, ubiquitin accumulation quantification, confocal microscopy, genetic rescue with SCF components EMBO reports High 34515398
2022 FBXO2 directly targets glycosylated SUN2 for ubiquitination and proteasomal degradation; transcription factor SOX6 promotes FBXO2 expression by binding a response element in the FBXO2 promoter, establishing a SOX6-FBXO2-SUN2 axis in ovarian cancer. Co-immunoprecipitation, ubiquitination assay, SOX6 promoter luciferase assay, siRNA knockdown/overexpression in vitro and in vivo Cell death & disease Medium 35525855
2025 FBXO2 directly interacts with LCN2 via its FBA domain, promoting K27-linked polyubiquitination of LCN2 and its proteasomal degradation, thereby suppressing ferroptosis; FBXO2 also activates PINK1/Parkin-dependent mitophagy under oxidative stress. Co-immunoprecipitation, ubiquitination assay (K27-linkage specific), proteomics, AAV9-mediated overexpression in vivo, FBXO2 KO mice Advanced science (Weinheim, Baden-Wurttemberg, Germany) Medium 40791152
2025 FBXO2 directly binds to p53 and promotes its ubiquitination and proteasomal degradation; p53 knockdown partially reverses the growth arrest caused by FBXO2 knockdown in papillary thyroid carcinoma cells. Co-immunoprecipitation, ubiquitination assay, epistasis rescue experiment, in vivo xenograft Scientific reports Medium 39343799
2025 FBXO2 colocalizes and directly interacts with KPTN via its F-box-associated domain, promoting K48- and K63-linked polyubiquitination of KPTN at K49, K67, K262, and K265; this disrupts KICSTOR complex assembly (impairing GATOR1 lysosomal recruitment) and promotes mTORC1 activation and hepatocellular carcinoma progression. Co-immunoprecipitation, in vitro ubiquitination with site-specific mutants, colocalization imaging, mTORC1 activity assays, in vivo tumor models The Journal of clinical investigation High 41401028
2025 FBXO2 directly binds WEE1 through its FBA domain, promoting WEE1 ubiquitination and degradation; WEE1 depletion partially abolishes the tumorigenic effects of FBXO2 silencing in renal cell carcinoma xenograft models. Co-immunoprecipitation, mass spectrometry, ubiquitination assay, domain mapping, in vivo xenograft rescue experiment Cellular oncology (Dordrecht, Netherlands) Medium 40676478
2025 FBXO2 directly binds YTHDF2 via its C-terminal region and promotes ubiquitination at K286, leading to YTHDF2 degradation; YTHDF2 enhances PCa progression by modulating m6A methylation of CDKN1C mRNA. Co-IP/mass spectrometry, Western blot, ubiquitination assay with site-specific mutants, rescue experiments Cell death & disease Medium 41461633
2025 FBXO2 targets USP49 deubiquitinase for ubiquitin-mediated proteasomal degradation; FBXO2 depletion stabilizes USP49 and suppresses HCC progression and sorafenib resistance. Co-immunoprecipitation, in vivo ubiquitination assay, cycloheximide chase, functional rescue by USP49 silencing, xenograft models Frontiers in immunology Medium 41035649
2025 FUT2 scaffolds FBXO2 to facilitate K362 site-specific ubiquitination and proteasomal degradation of transcription factor NR2F2, suppressing LCN2 expression and reversing immunosuppression in pancreatic cancer radiotherapy. In vivo CRISPR screen, co-immunoprecipitation, ubiquitination assay with site-specific mutants, gene expression analysis Cell death & disease Medium 41436429
2025 FBXO2 promotes K63-linked ubiquitination of IL6ST (gp130), activating STAT3 signaling during decidualization; cadmium suppresses FBXO2, impairing IL6ST/STAT3 signaling and decidualization. Proteomic analysis, co-immunoprecipitation, ubiquitination assay (K63-linkage), FBXO2 overexpression rescue in vitro and in vivo Ecotoxicology and environmental safety Medium 41076860
2026 FBXO2 interacts with FABP5 and promotes its lysosomal degradation via chaperone-mediated autophagy; this decreases intracellular PUFAs and increases resistance to ferroptosis in colorectal cancer cells. Co-immunoprecipitation, lysosomal degradation assay, FABP5 stability assay, PUFA supplementation rescue Redox biology Medium 41604941

Source papers

Stage 0 corpus · 48 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2007 Structural basis for the selection of glycosylated substrates by SCF(Fbs1) ubiquitin ligase. Proceedings of the National Academy of Sciences of the United States of America 74 17389369
2007 Selective cochlear degeneration in mice lacking the F-box protein, Fbx2, a glycoprotein-specific ubiquitin ligase subunit. The Journal of neuroscience : the official journal of the Society for Neuroscience 65 17494702
1998 A novel F box protein, NFB42, is highly enriched in neurons and induces growth arrest. The Journal of biological chemistry 60 9857061
2022 FBXO2 targets glycosylated SUN2 for ubiquitination and degradation to promote ovarian cancer development. Cell death & disease 44 35525855
2004 The cochlear F-box protein OCP1 associates with OCP2 and connexin 26. Hearing research 39 15109709
2020 Fbxo2 mediates clearance of damaged lysosomes and modifies neurodegeneration in the Niemann-Pick C brain. JCI insight 38 32931479
2015 Loss of F-box only protein 2 (Fbxo2) disrupts levels and localization of select NMDA receptor subunits, and promotes aberrant synaptic connectivity. The Journal of neuroscience : the official journal of the Society for Neuroscience 38 25878288
2018 Epstein-Barr virus activates F-box protein FBXO2 to limit viral infectivity by targeting glycoprotein B for degradation. PLoS pathogens 36 30052682
2016 Aberrant Expression of FBXO2 Disrupts Glucose Homeostasis Through Ubiquitin-Mediated Degradation of Insulin Receptor in Obese Mice. Diabetes 36 27932386
2017 An engineered high affinity Fbs1 carbohydrate binding protein for selective capture of N-glycans and N-glycopeptides. Nature communications 34 28534482
2005 Thermodynamic analysis of interactions between N-linked sugar chains and F-box protein Fbs1. Journal of medicinal chemistry 34 15857118
2014 F-box only protein 2 (Fbxo2) regulates amyloid precursor protein levels and processing. The Journal of biological chemistry 31 24469452
2016 SYVN1, NEDD8, and FBXO2 Proteins Regulate ΔF508 Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Ubiquitin-mediated Proteasomal Degradation. The Journal of biological chemistry 29 27756846
2020 FBXO2 Promotes Proliferation of Endometrial Cancer by Ubiquitin-Mediated Degradation of FBN1 in the Regulation of the Cell Cycle and the Autophagy Pathway. Frontiers in cell and developmental biology 28 32984335
2017 FBXO2, a novel marker for metastasis in human gastric cancer. Biochemical and biophysical research communications 27 29269301
2007 A neural-specific F-box protein Fbs1 functions as a chaperone suppressing glycoprotein aggregation. The Journal of biological chemistry 27 17215248
2001 OCP1, an F-box protein, co-localizes with OCP2/SKP1 in the cochlear epithelial gap junction region. Hearing research 27 11470190
2023 Quantitative proteomic landscapes of primary and recurrent glioblastoma reveal a protumorigeneic role for FBXO2-dependent glioma-microenvironment interactions. Neuro-oncology 24 35802605
2021 FBXO2/SCF ubiquitin ligase complex directs xenophagy through recognizing bacterial surface glycan. EMBO reports 24 34515398
2004 The neural F-box protein NFB42 mediates the nuclear export of the herpes simplex virus type 1 replication initiator protein (UL9 protein) after viral infection. Proceedings of the National Academy of Sciences of the United States of America 22 15010529
2003 Replication-initiator protein (UL9) of the herpes simplex virus 1 binds NFB42 and is degraded via the ubiquitin-proteasome pathway. Proceedings of the National Academy of Sciences of the United States of America 22 12904574
2019 Comparative ultrafast spectroscopy and structural analysis of OCP1 and OCP2 from Tolypothrix. Biochimica et biophysica acta. Bioenergetics 21 31734194
2020 FBXO2 modulates STAT3 signaling to regulate proliferation and tumorigenicity of osteosarcoma cells. Cancer cell international 19 32549792
2018 Fbxo2VHC mouse and embryonic stem cell reporter lines delineate in vitro-generated inner ear sensory epithelia cells and enable otic lineage selection and Cre-recombination. Developmental biology 15 30179592
2015 The Structural Differences between a Glycoprotein Specific F-Box Protein Fbs1 and Its Homologous Protein FBG3. PloS one 15 26460611
2003 Toward an understanding of cochlear homeostasis: the impact of location and the role of OCP1 and OCP2. Acta oto-laryngologica 15 12701741
2025 FBXO2 Alleviates Intervertebral Disc Degeneration via Dual Mechanisms: Activating PINK1-Parkin Mitophagy and Ubiquitinating LCN2 to Suppress Ferroptosis. Advanced science (Weinheim, Baden-Wurttemberg, Germany) 12 40791152
2017 Genetic Analysis of FBXO2, FBXO6, FBXO12, and FBXO41 Variants in Han Chinese Patients with Sporadic Parkinson's Disease. Neuroscience bulletin 12 28341977
2022 Structure-function-dynamics relationships in the peculiar Planktothrix PCC7805 OCP1: Impact of his-tagging and carotenoid type. Biochimica et biophysica acta. Bioenergetics 9 35752265
2024 Integrated analysis of scRNA-seq and bulk RNA-seq identifies FBXO2 as a candidate biomarker associated with chemoresistance in HGSOC. Heliyon 7 38590858
2024 FBXO2 promotes the progression of papillary thyroid carcinoma through the p53 pathway. Scientific reports 7 39343799
2010 FBG1 is a promiscuous ubiquitin ligase that sequesters APC2 and causes S-phase arrest. Cell cycle (Georgetown, Tex.) 7 21135578
2024 FBXO2 as a switch guides a special fate of tumor clones evolving into a highly malignant transcriptional subtype in oral squamous cell carcinoma. Apoptosis : an international journal on programmed cell death 6 39487312
2023 Sleeve Gastrectomy Improves Hepatic Glucose Metabolism by Downregulating FBXO2 and Activating the PI3K-AKT Pathway. International journal of molecular sciences 6 36982617
2023 Post-Transcriptional Regulator RBM47 Stabilizes FBXO2 mRNA to Advance Osteoarthritis Development: WGCNA Analysis and Experimental Validation. Biochemical genetics 5 38070024
2016 Structural analysis of a function-associated loop mutant of the substrate-recognition domain of Fbs1 ubiquitin ligase. Acta crystallographica. Section F, Structural biology communications 5 27487926
2015 FBG1 Is the Final Arbitrator of A1AT-Z Degradation. PloS one 5 26295339
2011 The Nogo receptor 2 is a novel substrate of Fbs1. Biochemical and biophysical research communications 5 22206664
2009 Conformational stabilities of guinea pig OCP1 and OCP2. Biophysical chemistry 4 19671485
2025 FBXO2 promotes hepatocellular carcinoma progression and sorafenib resistance by targeting USP49 for proteasomal degradation. Frontiers in immunology 2 41035649
2022 SCFFBS1 Regulates Root Quiescent Center Cell Division via Protein Degradation of APC/CCCS52A2. Molecules and cells 2 36116942
2025 Fbxo2 inhibits cell proliferation, migration and invasion by the ubiquitin-mediated degradation of WEE1 in renal cell carcinoma. Cellular oncology (Dordrecht, Netherlands) 1 40676478
2025 FBXO2-mediated KPTN ubiquitination promotes amino acid-dependent mTORC1 signaling and tumor growth. The Journal of clinical investigation 1 41401028
2025 FUT2 enhances anti-tumor immunity in pancreatic cancer radiotherapy by driving FBXO2-mediated degradation of NR2F2. Cell death & disease 1 41436429
2026 p53 and fatty acids collaborate to trigger ferroptosis via the FBXO2-FABP5 axis in colorectal cancer. Redox biology 0 41604941
2025 Research advancements regarding the relationship between FBXO2 and malignant tumors (Review). Molecular medicine reports 0 40999994
2025 Cadmium disrupts IL6ST/STAT3 signaling involving FBXO2 in decidualization: Environmental trigger of spontaneous abortion. Ecotoxicology and environmental safety 0 41076860
2025 Fbxo2 suppresses prostate cancer progression by regulating YTHDF2 ubiquitination and degradation. Cell death & disease 0 41461633